DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20211014

Efficacy and safety of remogliflozin etabonate in type 2 diabetes mellitus patients in a tertiary care hospital

Ameera Neelam, Anand Kanaki

Abstract


Background: Incidence and prevalence of diabetes have been steadily increasing with a raise of global prevalence about 8.5%. The major types of diabetes are differentiated by insulin deficiency versus insulin resistance. SGLT2 inhibitors are a new class of drugs that act by inhibiting glucose reabsorption in the proximal renal tubules. Remogliflozin a prodrug of remogliflozin, which is a potent and selective sodium-glucose co-transporter-2 inhibitor was used for the study. The objective of the study was to evaluate the efficacy and safety of Remogliflozin etabonate in reducing HbA1C and serum glucose in type II diabetics.

Methods: This was a prospective observational study was done for 3 months. HbA1C, FBS and PPBS readings were noted and then the subjects were introduced to Remoglifozin 100 mg twice a day. At the end of 12 weeks HbA1C, FBS and PPBS were noted. The obtained data was analysed for its efficacy and safety.

Results: The study included 22 male subjects and 28 females. Before Remoglifzoin was given the mean HbA1C level was 8.23± 0.798, mean FBS was 179± 29.79 and PPBS was 299.38± 24.21. Remoglifozin 100 mg was given and the mean HbA1C level was 7.52± 0.765, mean FBS was 166.30± 32.13 and mean PPBS was 249.46± 18.21. Post 3 months of Remoglifzoin induction a reduction in HbA1C, FBS and PPBS was seen.

Conclusions: This study concludes Remoglifozin etabonate of 100 mg when given twice daily reduced the HbA1C levels, FBS and PPBS levels significantly.


Keywords


Remoglifozin etabonate, Glycated hemoglobin test, Fasting blood glucose, Post prandial blood glucose

Full Text:

PDF

References


Longo D, Kasper DL, Fauci AS, Hauser S, Jameson JL, Loscalzo J et al, editors. Harrison’s principles of internal medicine, 19th ed. [Internet]. New York: The McGraw-Hill Companies, Inc. 2015.

Weber DR, Jospe N. Diabetes Mellitus: Classification of Diabetes MellitusIn: Kliegman, Behrman, Jenson, editors, Nelson Textbook of Pediatrics. 21st edition, New Delhi: Elsevier. 2020;2:11814-11936.

World health organization. Diabets- health topics. Geneva, 8 June 2020. https://www.who.int/health-topics/diabetes#tab=tab_1. Last accessed on 13th July 2020.

World health organization. Diabets- key facts. Geneva, 8 June 2020. https://www.who.int/news-room/fact-sheets/detail/diabetes. Last accessed on 13th July 2020.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collaboration, Lancet Publication. 2010;26(375):2215-2222.

Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Jennifer BG et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015;66(3):545.

World health organization. Diabetes Programme-About diabetes-Complications of diabetes. Geneva, June 2020. https://www.who.int/diabetes/action_online/basics/en/index3.html. Last accessed on 13th July 2020.

Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-79.

Kapur A, O’Connor-Semmes R, Hussey EK, Robert LD, Wenli T, Marcus H et al. First human dose-escalation study with remogliflozinetabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol. 2013;14(1):26.

Type II diabetes diagnostic criteria by American diabetic association. Updated: Feb 2020.

Mala D, Thacker SRA, Paramesh S, Mohan B, Chawla M et al. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co‑Transporter‑2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24‑Week, Randomized, Double‑Blind, Active‑Controlled Trial.

Pattanaik SR. Efficacy of Addition of Remogliflozin to Type-2 Diabetic Patients, Uncontrolled with Dual Drug Treatment with Metformin and Glimeperide, an Observational Study. International Journal of Contemporary Medicine Surgery and Radiology. 2020;5(3):1-3.

Mohan V, Mithal SR, Joshi SR, Aravind, Chowdhury S. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Dovepress Journal. Drug Design, Development and Therapy. 2020;14:2487-250.

Dobbins RL, O’Connor-Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab. 2012;14:15-22.